| Phase | Design | Status | Key Findings | |-------|--------|--------|--------------| | (2022‑2023) | Randomized, double‑blind, single‑ascending dose (SAD) & multiple‑ascending dose (MAD) in healthy volunteers (n ≈ 80). | Completed | - Good tolerability up to 200 mg QD . - Linear PK: t½ ≈ 12 h , Cmax reached ~3 h. - No serious adverse events (SAEs); most common AEs: mild headache, transient GI upset. | | Phase IIa (2024) | 12‑week, double‑blind, placebo‑controlled trial in mild‑to‑moderate AD (n = 150). Primary endpoint: change in ADAS‑Cog13 . | Completed (positive trend) | - ΔADAS‑Cog13 = –2.1 vs –0.7 for placebo (p = 0.07). - Significant ↓ CSF neurofilament light (NfL) (p = 0.02). - Safety profile remained clean; one SAE (hospitalization for pneumonia) deemed unrelated. | | Phase IIb (2025‑2026) | Ongoing 24‑week, multicenter, adaptive‑design in early AD (n ≈ 380) + type‑2 diabetes sub‑cohort (n ≈ 150). Primary: Cognitive Composite (CDR‑SB) ; secondary: HbA1c , MRI hippocampal volume , CSF Aβ42/40 . | Ongoing (mid‑trial read‑out expected Q4 2026) | - Interim pharmacodynamic data show dose‑dependent ↑cAMP in peripheral blood mononuclear cells (PBMCs). - No drug‑drug interaction signals with metformin or donepezil. | | Phase III | Planned for 2028 (if Phase IIb meets predefined futility thresholds). | Not started | Targeted to be a dual‑indication (AD + metabolic syndrome). |
And somewhere, far beyond the reaches of human knowledge, a silent chorus waited, ready to be heard. The universe, once a vast expanse of silence, now thrummed with the promise of connection, all because a curious linguist had placed her hand upon a black cube and chose to listen. JUQ-473
The captain turned to Lena, his face reflecting a mixture of awe and relief. “You did it, Doctor. You gave us a voice in the darkness.” | Phase | Design | Status | Key
Evaluation of JUQ-473 should measure: